Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells

被引：0
|
作者：
Caroland, Kailey
Shi, Changyou
Lo, Hui-Wen
Lin, Jiayuh
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4610
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4610
引用
收藏
页数：2
相关论文
共 50 条
  • [41] FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway
    Guanglei Chen
    Lisha Sun
    Xi Gu
    Liping Ai
    Jie Yang
    Zhan Zhang
    Pengjie Hou
    Yining Wang
    Xunyan Ou
    Xiaofan Jiang
    Xinbo Qiao
    Qingtian Ma
    Nan Niu
    Jinqi Xue
    Hao Zhang
    Yongliang Yang
    Caigang Liu
    Science China Life Sciences, 2023, 66 : 2805 - 2817
  • [42] FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway
    Chen, Guanglei
    Sun, Lisha
    Gu, Xi
    Ai, Liping
    Yang, Jie
    Zhang, Zhan
    Hou, Pengjie
    Wang, Yining
    Ou, Xunyan
    Jiang, Xiaofan
    Qiao, Xinbo
    Ma, Qingtian
    Niu, Nan
    Xue, Jinqi
    Zhang, Hao
    Yang, Yongliang
    Liu, Caigang
    SCIENCE CHINA-LIFE SCIENCES, 2023, 66 (12) : 2805 - 2817
  • [43] Lapatinib induces IL-6 expression via MAPK pathway in triple-negative breast cancer cells
    Hsiao, Yu-Chun
    Chen, Yun-Ju
    Tang, Chih-Hsin
    Huang, Wei-Chien
    CANCER RESEARCH, 2014, 74 (19)
  • [44] Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
    J L Dean
    C Thangavel
    A K McClendon
    C A Reed
    E S Knudsen
    Oncogene, 2010, 29 : 4018 - 4032
  • [45] Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
    Dean, J. L.
    Thangavel, C.
    McClendon, A. K.
    Reed, C. A.
    Knudsen, E. S.
    ONCOGENE, 2010, 29 (28) : 4018 - 4032
  • [46] CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
    Laderian, Bahar
    Fojo, Tito
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 395 - 403
  • [47] CREBBP alterations lead to CDK4/6 inhibitor sensitivity in triple negative breast cancer
    Natrajan, Rachael
    CANCER RESEARCH, 2020, 80 (04)
  • [48] Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A
    Kuo, Yueh-Hsiung
    Chiang, En-Pei Isabel
    Chao, Che-Yi
    Rodriguez, Raymond L.
    Chou, Pei-Yu
    Tsai, Shu-Yao
    Pai, Man-Hui
    Tang, Feng-Yao
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (03) : 480 - 493
  • [49] CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard
    Wolff, Antonio C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1993 - 1995
  • [50] Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
    Demirsoy, Seyma
    Tran, Ha
    Liu, Joseph
    Li, Yunzhan
    Yang, Shengyu
    Aregawi, Dawit
    Glantz, Michael J.
    Jacob, Naduparambil K.
    Walter, Vonn
    Schell, Todd D.
    Olmez, Inan
    CANCERS, 2024, 16 (12)
12345